Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018462 | 0.92 | BTK (0.53) | CDC7BTKERBB2BRAFTNNI3K | |
| SCHEMBL2019597 | 0.90 | BTK (0.53) | BTKERBB2BRAFTNNI3K | |
| SCHEMBL27904179 | 0.88 | BTK (0.52) | CDC7BTKERBB2BRAFTNNI3K | |
| SCHEMBL15372896 | 0.88 | BTK (0.52) | BTKERBB2BRAFTNNI3K | |
| SCHEMBL2019287 | 0.85 | EGFR (0.59) | BTKBRAFTNNI3K | |
| SCHEMBL2022001 | 0.85 | BTK (0.60) | CDC7BTKBRAFTNNI3KROCK2 | |
| SCHEMBL2024535 | 0.85 | BTK (0.64) | CDC7BTKROCK2MAP4K4PIM1 | |
| SCHEMBL2019570 | 0.85 | BTK (0.49) | BTKERBB2 | |
| SCHEMBL12635826 | 0.84 | BTK (0.56) | CDC7BTKBRAFTNNI3KROCK2 | |
| SCHEMBL12493140 | 0.84 | BTK (0.56) | CDC7BTKBRAFTNNI3KROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2519525-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | DPYD, TYMP, DHFR | CDC7 996/4885ALK 1462/4885BTK 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.